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1820Objective: Some patients with clinical T1 N0M0 lung adenocarcinoma have pathologic lymph node metastasis.
However, neither the precise prognosis nor the factors predictive of the prognosis of such patients have yet been
identified.
Methods: Our study included 609 patients with clinical T1 N0 M0 lung adenocarcinoma; 568 (93.3%) patho-
logic node negative [pN(–)] and 41 (6.7%) pathologic node positive [pN(þ)] patients, diagnosed after complete
surgical resection. The association between prognosis and pathologic findings was analyzed retrospectively.
Results: pN(þ) patients had a significantly lower lepidic growth component ratio (10% vs 50%), a higher
lymphatic invasion (LI) rate (68% vs 11%), vessel invasion rate (59% vs 14%), and visceral pleural invasion
rate (29% vs 9%), compared with pN(–) patients (all Ps< .001). Surprisingly, 13 of 41 (32%) pN(þ) patients
showed no LI. In pN(–) patients, a multivariate analysis of recurrence-free survival revealed that lower lepidic
growth component ratio, and lymphatic, vessel, and pleural invasion were significantly correlated with a poor
prognosis (P ¼ .008, .045, .031, and .024). However, in pN(þ) patients, the multivariate analysis of
recurrence-free survival showed that only LI was a significant independent prognostic factor (P ¼ .037).
The 5-year recurrence-free survival rates were as follows: 91.2% for pN(–)/LI(–) patients, 68.2% for pN(–)/
LI(þ) patients, 63.5% for pN(þ)/LI(–) patients, and 41.9% for pN(þ)/LI(þ) patients. LI status stratified the
prognosis not only in patients with no nodal metastasis but also in those with metastasis.
Conclusions: LI, which is not always present in node-positive adenocarcinoma, is an important prognostic var-
iable in patients with node involvement. (J Thorac Cardiovasc Surg 2014;147:1820-6)Earn CME credits at
http://jtcvs.com/cme/home
Fluorescence deoxyglucose (FDG) positron emission to-
mography (PET) is commonly used for preoperative assess-
ment of primary tumors, lymph nodes, and distant
metastasis to determine staging and treatment strategy,1-3
thereby improving the accuracy of the definition of
clinical stage IA compared with only computed
tomography assessment.1 This has changed the population
of patients with clinical stage IA lung adenocarcinoma.1,4-7
However, some clinical lymph node-negative [cN(–)]e Departments of Surgical Oncologya and Pathology,b Hiroshima University,
hima, Japan; Department of Thoracic Surgery,c Kanagawa Cancer Center,
hama, Japan; Department of Thoracic Surgery,d Cancer Institute Hospital, To-
apan; and Department of Thoracic Surgery,e Hyogo Cancer Center, Akashi,
.
res: Authors have nothing to disclose with regard to commercial support.
d for publication Aug 5, 2013; revisions received Oct 22, 2013; accepted for
ation Nov 22, 2013; available ahead of print Feb 7, 2014.
for reprints: Morihito Okada, MD, PhD, Department of Surgical Oncology,
hima University, Hiroshima, Japan, 1-2-3 Kasumi, Minami-ku, Hiroshima,
551, Japan (E-mail: morihito1217@hiroshima-u.ac.jp).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.11.050
The Journal of Thoracic and Cardiovascular Surpatients show positive pathologic lymph node [pN(þ)]
metastasis. It is speculated that a cN(–) but pN(þ) status in-
dicates an initial lymph node metastatic condition, because
the accumulation of FDG in the lymph node could be signif-
icantly higher in patients with massive lymph node metas-
tasis. Therefore, cN(–)/pN(þ) patients may have a better
prognosis than cN(þ)/pN(þ) patients, or a similar prog-
nosis to cN(–)/pN(–) patients. In addition, no studies have
identified the prognostic factors in cN(–)/pN(þ) patients.
In our study, we evaluated the clinicopathologic findings
and prognosis of patients with clinical T1 N0M0 lung adeno-
carcinoma according to lymph node status, or other patho-
logic status. First, we examined the pathologic findings to
identify predictive factors for recurrence-free survival (RFS)
among patients with clinical stage IA lung adenocarcinoma.
Multivariate analysis revealed that lymphatic invasion (LI)
statuswasapredictive factor, both inpatientswithandwithout
node involvement.Next,we assessed the prognosis of patients
with and without lymph node involvement according to LI
status. The results highlight the importance of the LI status
in patients with clinical T1 N0 M0 lung adenocarcinoma.MATERIALS AND METHODS
Patient Population
Our study included 611 patientswho underwent complete surgical resec-
tion of clinical stage IA lung adenocarcinoma at the Hiroshima Universitygery c June 2014
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CT ¼ computed tomography
FDG ¼ fluorescence deoxyglucose
GGO ¼ ground glass opacity
HU ¼ Haunsfield unit
LC ¼ lepidic component
LI ¼ lymphatic invasion
OS ¼ overall survival
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RFS ¼ recurrence-free survival
SUV ¼ standardized uptake value
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SHospital (Hiroshima, Japan), the Kanagawa Cancer Centre (Yokohama,
Japan), the Cancer Institute Hospital (Tokyo, Japan), and the Hyogo Cancer
Centre (Akashi, Japan) between April 2007 and December 2010. Approval
was given by the institutional review boards of the participating institutions,
all of which waived the requirement for informed consent from individual
patients for this retrospective review of the prospective database. Two pa-
tients were excluded because they lacked a lepidic component (LC) ratio.
The data from the remaining 609 patients were analyzed retrospectively.
High-resolution computed tomography (CT) and FDG-PET/CT, followed
by a curative R0 resection were performed for all patients staged according
to the TNM Classification of Malignant Tumours.8 Endobronchial ultraso-
nography or mediastinoscopy was not performed routinely because all pa-
tients underwent preoperative high-resolution CT and FDG-PET/CT; the
high-resolution CT results showed no swelling of mediastinal or hilar
lymph nodes and FDG-PET revealed no accumulation of FDG in those
lymph nodes. Lymph node swelling was defined when the diameter of a mi-
nor axis is larger than 10mm. Sublobar resection was performed in cases of
complete removal of the disease with appropriate surgical margins for a
peripheral T1a N0M0 tumor. Wedge resection without lymph node assess-
ment was performed for ground glass opacity (GGO) tumors on high-
resolution CT, which was regarded as a node-negative and noninvasive
tumor in a prospective study.9 Segmentectomy with hilar and mediastinal
lymph node dissection were performed for a GGO-mixed tumor. If lymph
node involvement was detected on an intraoperative frozen section of any
lymph node, the procedurewas converted to a standard lobectomy. All other
patients underwent a standard lobectomy. The inclusion criteria included
preoperative staging determined by high-resolution CT and FDG-PET/
CT, curative surgery without any induction therapy, and a definitive histo-
pathologic diagnosis of lung adenocarcinoma. Patients with incompletely
resected tumors (R1 or R2), and those with multiple tumors or previous
lung surgery, were excluded from the data set.
Pathology Studies
Sections were fixed with 10% formalin and embedded in paraffin.
Consecutive 4-mm sections were cut and 1 slice per 5 mm was examined
under a microscope for the pathologic assessment. Histologic diagnosis
and staging was based on the latest edition of the World Health Organiza-
tion classification scheme.10 The histologic type of adenocarcinoma and
the presence of lymphatic involvement were determined using
hematoxylin-eosin stained tissue. If the findings could not be determined
by hematoxylin-eosin staining alone, immunohistochemical staining was
carried out as necessary. An LC ratio was defined as the proportion of
LC area relative to the entire tumor. LI and blood vessel invasion were as-
sessed by immunohistochemistry for D2-40, which stains lymphatic ducts,
and Van Gieson staining of the elastic fiber of the vessels. LI and blood
vessel invasion were determined when spreading through or penetration
was detected as an extension of a malignant neoplasm. To evaluate pleural
invasion, elastic tissue fibers were subjected to Van Gieson staining. PleuralThe Journal of Thoracic and Carinvasion was determined if cancer cells had invaded beyond the elastic
layer, including invasion into the visceral pleural surface, or neighboring
organs. Histologic examinations were determined by pathologists from
each institution for the purposes of this study.
HRCT
A 16-row multidetector CT was used to obtain chest images. For high-
resolution images of the tumors, the following parameters were used: 120
kVp, 200 mA, 1 to 2 mm section thickness, 5123 512 pixel resolution, 0.5
to 1.0 second scanning time, a high spatial reconstruction algorithm with a
20 cm field of view, andmediastinal (level, 40 Haunsfield unit [HU]; width,
400 HU) and lung (level, 600 HU; width, 1600 HU) window settings.
GGO was defined as a misty increase in lung attenuation that did not
obscure underlying vascular markings. CT scans were reviewed and tumor
sizes determined by radiologists from each institution.
FDG-PET/CT
Patients were instructed to fast for at least 4 hours before intravenous
injection of 74 to 370 MBq FDG and then to relax for at least 1 hour before
the FDG-PET/CT scan. For imaging, Biograph Sensation 16 (Siemens
Healthcare, Erlangen, Germany), Aquiduo (Toshiba Medical Systems Cor-
poration, Tochigi, Japan), or Discovery ST (GEHealthcare, Little Chalfont,
United Kingdom) integrated 3-dimensional PET/CT scanners were used.
Low-dose nonenhanced CT images of 2 to 4 mm section thickness were
taken from the head to the pelvis of each patient. An anthropomorphic
body phantom (NEMA NU2-2001; Data Spectrum Corp, Hillsborough,
NC) was used to minimize variations in standardized uptake values
(SUVs) among the institutions.11,12 The original SUVmax values were
determined by radiologists from each institution for the purposes of this
study. On FDG-PET/CT images, all lymph nodes in the thorax with FDG
uptake no greater than the normal background activity of the mediastinal
blood pool—the SUVmax of which was<1.5, regardless of size—were
considered cN0. A lymph node where the SUVmax was 1.5 or more
was considered ‘‘suspicious for malignancy.’’ However, even lymph nodes
with high FDG uptake, when they showed higher attenuation than medias-
tinal structures (great vessels) or benign calcification (central, nodular,
diffuse, or popcorn-like), were also considered benign.13
Follow-up Evaluation
All patients who underwent lung resections were followed-up from the
day after surgery. Postoperative follow-up procedures, including a phys-
ical examination and chest radiograph every 3 months and chest and
abdominal CT examinations every 6 months, were performed for the first
2 years. Thereafter, a physical examination and chest radiograph were per-
formed every 6 months, and a chest CT examination was performed
annually.
Statistical Analyses
Patients with clinical stage IA lung adenocarcinoma were included in
the analysis. AMann-WhitneyU test was used to compare continuous vari-
ables and the c2 test or Fisher exact test was used for categorical variables.
RFS was defined as the length of time after primary surgical treatment for a
cancer ends that the patient survived without any sign or symptom of the
cancer. Recurrence was defined as patients having symptoms caused by
recurring cancer and suspicious lesions that were diagnosed as recurrent tu-
mors by biopsies. If suspicious lesions were not diagnosed as recurrence,
by biopsy, the ‘‘recurrence’’ was comprehensively and clinically defined
by radiographic findings, including CTand FDG-PET/CT. RFS and overall
survival (OS) curves were calculated using the Kaplan-Meier method. Uni-
variate survival analysis was performed using the log-rank test for compar-
isons of curves. ACox regression model was used to calculate P values and
hazard ratios in the univariate and multivariate analyses. The prognostic
analysis was performed during August 2012. All statistical analyses werediovascular Surgery c Volume 147, Number 6 1821
TABLE 1. Clinicopathologic findings in patients with clinical stage IA
lung adenocarcinoma with or without lymph node metastasis
Finding
Node negative
(n ¼ 568)
Node positive
(n ¼ 41) P value
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Sperformed using EZR (Saitama Medical Centre, Jichi Medical University,
Saitama, Japan),14 which is a graphical user interface for R (The R Foun-
dation for Statistical Computing, version 2.13.0, Vienna, Austria). More
precisely, it is a modified version of R Commander (version 1.6-3), which
includes statistical functions frequently used in biostatistics.Age
Median 66 65 .33
Interquartile range 60.75-73 56-73
Sex
Female 322 (57%) 22 (54%) .19
Male 246 (43%) 19 (46%)
CEA
Median 2.5 3.6 .25
Interquartile range 1.5-3.6 1.1-113.8
Size*
Median 2.0 2.2 .060
Interquartile range 1.5-2.4 2.55-4.2
GGOy ratio
Median 40 0 <.001
Interquartile range 10-80 0-10
SUV max
Median 1.5 3.6 <.001
Interquartile range 0.9-2.6 2.3-4.9
LC ratio
Median 50 10 <.001
Interquartile range 10-90 0-20
Lymphatic invasion
Negative 507 (89%) 13 (32%) <.001
Positive 61 (11%) 28 (68%)
Blood vessel invasion
Negative 488 (86%) 17 (41%) <.001RESULTS
Clinical Outcomes in Patients With Lung
Adenocarcinoma
The median follow-up time was 41.6 months. Lobec-
tomy, segmentectomy, and wedge resection were performed
in 375, 97, and 137 patients, respectively. The 30-day mor-
tality rate was 0%. As shown in Table 1, 41 patients (6.7%)
had lymph node metastasis in the clinical stage IA lung
adenocarcinoma cohort. No significant difference between
pN(–) and pN(þ) patients was detected in terms of age,
sex, and carcinoembryonic antigen value, whereas a mar-
ginal difference was seen for tumor size on preoperative
high-resolution CT. Regarding the clinical variables, lower
GGO ratios and higher SUVmax were observed in the Nþ
group compared with the N– group. In terms of pathologic
variables, a lower LC ratio and higher positive rate of LI,
blood vessel invasion, and pleural invasion were detected
in pN(þ) patients. Thirteen of 41 pN(þ) patients showed
no LI. As shown in Figure 1,A, clinical stage IA lung adeno-
carcinoma patients with lymph node metastasis had a lower
RFS rate than those without lymph node metastasis
(P<.001).Positive 80 (14%) 24 (59%)
Pleural invasion
Negative 515 (91%) 29 (71%) <.001
Positive 53 (9%) 12 (29%)
CEA, Carcinoembryonic antigen; GGO, ground-glass opacity; SUV, standardized up-
take value; LC, lepidic component. *Tumor size on the high-resolution computed to-
mography scan. yGGO ratio on the high-resolution computed tomography scan.Univariate and Multivariate Analyses of Prognosis
According to Pathologic Variables, by Lymph Node
Status
Univariate and multivariate analyses of the clinical and
pathologic variables were performed to ascertain the most
important predictive factor. Univariate analyses were per-
formed on RFS and OS, whereas further analyses, including
multivariate analyses, were performed on RFS because OS
was more immature than RFS. The pathologic variables
included LC ratio, LI status, blood vessel invasion status,
pleural invasion status, and lymph node status. For the LC
ratio, 30% was used as a threshold because this is the
borderline for cT1 N0 M0 lung adenocarcinoma classified
as a high- or low-grade malignancy.2 Univariate analysis re-
vealed that pN(þ) patients with LI positive status [LI(þ)]
had a marginally poorer prognosis (P ¼ .059), whereas a
lower LC ratio and LIþ status, blood vessel invasion,
pleural invasion, or lymph node metastasis was significantly
correlated with a poor prognosis in both all patients in this
cohort, and in pN(–) patients (Table 2). Additionally, multi-
variate analysis showed that only LI positive status was a
prognostic factor in pN(þ) patients (P ¼ .037), whereas a
lower LC ratio and positive LI status, blood vessel invasion,
pleural invasion, or lymph node metastasis were prognostic
factors in both all patients and pN(–) patients (Table 3).1822 The Journal of Thoracic and Cardiovascular SurNext, we assessed the RFS of pN(–) and pN(þ) patients ac-
cording to their LI status. In both pN(–) and pN(þ) patients,
RFS rates were lower in LI(þ) status compared with LI
negative status [LI(–)] (P<.001 and P ¼ .059) (Figure 1,
B and C). The 3-year RFS and OS rates for each group
was as follows: pN(–)/LI(–) 93.4% and 96.7%, pN(–)/
LI(þ) 70.8% and 85.1%, pN(þ)/LI(–) 84.6% and
92.3%, and pN(þ)/LI(þ) 47.9% and 75.0%, respectively
(Table 2 and Figure 1, B-F). No significant difference was
detected between the pN(þ)/LI(–) and pN(–)/LI(þ) pa-
tients for RFS (P ¼ .62; Figure 1, D), whereas pN(þ)/
LI(–) and pN(–)/LI(–) patients, pN(þ)/LI(þ) and pN(–)/
LI(–) patients, and pN(þ)/LI(þ) and pN(–)/LI(þ) patients
exhibited significantly different RFS values (P ¼ .022,
<.001, and .011, respectively).
Clinicopathologic Findings in Nþ Patients
In Nþ patients, there were no significant differences be-
tween the LI(–) and LI(þ) groups in terms of age, sex,gery c June 2014
FIGURE 1. Kaplan-Meier recurrence-free survival (A-D) and overall survival (E and F) curves in patients with clinical stage IA lung adenocarcinoma
according to pathologic lymph node status and lymph node metastasis and lymphatic invasion (LI) status. A, Patients are classified into pathologic lymph
nodemetastasis negative (pN[–]) and positive (pN[þ]) groups. B, The pN(–) patients are classified into a lymphatic permeation negative (pN[–]/LI[–]) group
and a lymphatic permeation positive (pN[–]LI[þ]) group. C, The pN(þ) patients are classified into a lymphatic permeation negative (N[þ]LI[–]) group and
a lymphatic permeation positive (N[þ]LI[þ]) group. D, Recurrence-free survival curves of pN(þ)LI(–) and pN(–)LI(þ) patients are shown. E, The pN(–)
patients are classified into a pN(–)/LI(–) group and a pN(–)LI(þ) group. F, The pN(þ) patients are classified into an N(þ)LI(–) group and an N(þ)LI(þ)
group. *P<.001; **P ¼ .059; yP ¼ .62; zP ¼ .48.
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Scarcinoembryonic antigen values, preoperative tumor size,
and SUVmax values. Regarding pathologic findings, LI sta-
tus had no association with the LC ratio, blood vessel inva-
sion, and pleural invasion. Additionally, LI status had no
correlation with lymph node metastasis status, both single
or multiple station metastases (Table 4).The Journal of Thoracic and CarDISCUSSION
In this study, pN(þ)/LI(–) patients had a better prognosis
than pN(þ)/LI(þ) patients, whereas there were no signifi-
cant differences in the RFS between pN(þ)/LI(–) and
pN(–)/LI(þ) clinical stage IA lung adenocarcinoma pa-
tients at the participating institutions. LI status, which isdiovascular Surgery c Volume 147, Number 6 1823
TABLE 2. Univariate log-rank analysis of recurrence-free survival (RFS) and overall survival (OS) according to various factors in patients with
lung adenocarcinoma
Pathologic variable
All Node negative Node positive
3-y RFS rate (%) P value 3-y RFS rate (%) P value 3-y RFS rate (%) P value
LC ratio
30 95.2 <.0001 95.9 <.0001 57.1 .93
<30 78.2 81.4 60.5
Lymphatic invasion
Negative 93.1 <.0001 93.4 <.0001 84.6 .059
Positive 63.7 70.8 47.9
Blood vessel invasion
Negative 93.1 <.0001 94.3 <.0001 58.8 .93
Positive 63.7 71.0 60.6
Pleural invasion
Negative 93.1 <.0001 92.6 <.0001 57.1 .42
Positive 68.6 74.6 65.6
Lymph node metastasis
Negative 90.9 <.0001 90.9 — — —
Positive 59.9 — 59.9
All Node negative Node positive
3-y OS rate (%) P value 3-y OS rate (%) P value 3-y OS rate (%) P value
LC ratio
30 97.0 <.0001 97.3 <.0001 75.0 .76
<30 90.9 92.0 84.5
Lymphatic invasion
Negative 96.6 <.0001 96.7 <.0001 92.3 .490
Positive 83.5 85.1 75.0
Blood vessel invasion
Negative 96.4 <.0001 96.7 <.0001 88.2 .55
Positive 86.5 88.1 81.0
Pleural invasion
Negative 94.9 .0042 95.9 <.0001 100.0 .29
Positive 92.7 91.2 77.3
Lymph node metastasis
Negative 95.5 <.0001 95.5 — — —
Positive 83.6 — 83.6
LC, Lepidic component; RFS, recurrence-free survival; OS, overall survival.
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tive factor in patients with pathologic lymph node metas-
tasis, whereas the lymph node metastasis status is a strong
prognostic factor in patients with clinical T1 N0 M0 lung
adenocarcinoma.
It is reasonable that lymph node metastasis occurs after
cancer cells invade the lymphatic vessels around the tu-
mors; however, 13 of 41 (31.7%) patients with lung adeno-
carcinoma, whose LI status was negative, exhibited
metastasis to regional lymph nodes. One possible explana-
tion is the difficulty in examining all slices of a specimen;
some of the slices, including the tumor, could be patholog-
ically assessed. This could be missed if tumors had only
slight LI, and the LI status would be determined as negative.
Therefore, ‘‘no pathologic LI’’ could either mean no
massive LI, just a slight invasion, or it could mean that there1824 The Journal of Thoracic and Cardiovascular Surwas indeed no LI. This is especially the case in pNþ pa-
tients, where ‘‘no pathologic LI’’ indicates a slight LI.
Slight invasion means the initial period of lymphatic vessel
invasion and lymph node metastasis; therefore, patients
with slight invasion had a better prognosis than those with
massive invasion after complete surgical resection. In
pNþ patients the N1 rate was higher in pN(þ)/LI(–) pa-
tients compared with pN(þ)/LI(þ) patients, albeit nonsig-
nificantly so. This suggests that pN(þ)/LI(–) is indicative
of initial lymph node metastasis, as described above.
In pNþ patients, the N2:N1 ratio was higher in pN(þ)
LI(þ) than pN(þ)LI(–) patients, although the difference
was not statistically significant. The number of pNþ pa-
tients was too small to draw any conclusion; however, the
tumors that showed massive LI had a higher tendency to
progress to N2 disease than LI(–) tumors. Patients withgery c June 2014
TABLE 3. Multivariate Cox regression analysis of recurrence-free survival according to various factors
Pathologic variables
All Node negative Node positive
HR P value HR P value HR P value
LC ratio 0.44 .010 0.39 .008 1.7 .62
>30 vs<30 0.23-0.82 0.20-0.78 0.44-6.3
Lymphatic invasion 2.5 .001 1.9 .045 6.1 .037
Positive vs negative 1.4-4.3 1.0-3.5 1.3-28.7
Blood vessel invasion 1.8 .037 2.0 .031 0.87 .61
Positive vs negative 1.0-3.1 1.1-3.8 0.31-2.4
Pleural invasion 1.6 .11 2.1 .024 0.47 .19
Positive vs negative 0.91-2.7 1.1-3.9 0.14-1.5
Lymph node metastasis 1.9 .032 —* —* —* —*
Positive vs negative 1.1-3.4
LC, Lepidic component; HR, hazard ratio. *Not calculated.
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demonstrated to have a worse prognosis than patients with
lymph nodes completely replaced by tumors.15 This sug-
gests that the continuum from LI to lymph node micrometa-
stasis to lymph node replacement might be more complex
than previously believed.
As in previous reports, in all patients, multivariate anal-
ysis of RFS revealed a lower LC ratio, positive status of
lymph nodes, LI, blood vessel invasion, pleural invasion
and were poor prognostic factors as well as Nþ status in
this study.16,17 In contrast, all evaluated pathologic
variables, except for LI status, did not show potential as
predictive factors for patients with lymph node
involvement. Although lymphatic metastasis status was a
strong prognostic factor, LI status was also a significant
predictive factor of prognosis in patients with clinical
stage IA lung adenocarcinoma. In pNþ patients, LI status
had no association with either the clinical or pathologic
findings. Thus, the above findings strongly support the
significance of LI status as a predictive factor, particularly
in patients whose lymph node status is clinically negative
and pathologically positive. That is, poor prognosis
should be defined according to not only lymph node
status but also LI status. Other unknown factors may
more precisely determine the true patient population with
a poor prognosis. Although pNþ patients typically
receive adjuvant chemotherapy, such patients may be
classified into no-adjuvant, mild-adjuvant, and severe-
adjuvant groups using several predictive factors, including
LI status.
Two previous reports have demonstrated that LI status is
a poor prognostic factor in surgically resected non–small
cell lung cancer18,19 and a similar result was shown in
pathologic stage I or adenocarcinoma patients.
Additionally, LI status has been demonstrated to be a
prognostic factor regardless of lymph node status.18,19
However, these previous studies had some limitations; 1
was the quality of LI status evaluation. LI status was
evaluated using D2-40 immunostaining in this study,The Journal of Thoracic and Carwhereas only some tumors were assessed for LI status using
D2-40 in the report19 and the other did not distinguish LI
from blood vessel invasion.18 Thus, the quality of LI evalu-
ation was higher in our study. Another limitation is hetero-
geneity of the cohort. The analysis was performed only in
pathologic stage I patients in the previous studies to mini-
mize heterogeneity.18,19 However, that analysis of
pathologic stage I patients could not assess LI status in
pNþ patients. In our study, we evaluated LI status with
little heterogeneity in pNþ patients because we included
only clinical stage IA adenocarcinoma patients having
little heterogeneity.
The rate of lymph node involvement was 6.7% of clinical
stage IA lung adenocarcinoma patients in our study (41 out
of 609 cases). PET/CT examination has been shown to pro-
vide the most accurate preoperative diagnosis1,4 and results
in appropriate treatment. However, a new diagnostic
method is necessary to evaluate more accurately the
preoperative status of patients with clinical stage IA
adenocarcinoma and pathologic lymph node involvement
whose preoperative diagnostic modality included a PET
scan.
Few patients had lymph node metastasis in clinical stage
IA lung adenocarcinoma, which represents one of the main
limitations of this study; only a very small number of pa-
tients with lymph node involvement had a negative LI sta-
tus. This makes it difficult to conclude that the prognosis
of pN(þ)LI(–) patients is equivalent to that of pN(–)
LI(þ) patients; however, it cannot be denied that LI status
plays an important role in assessing patients with lymph
node metastasis. The lack of data about pathologic tumor
size or morbidity are also limitations of our study. Another
is that detailed numbers on patients who received postoper-
ative chemotherapy were not available. Postoperative
chemotherapy was performed when pathologic upstaging
or recurrence was detected. Additionally, although the
follow-up time was too short to assess OS in this study,
the OS curves showed similar tendencies to RFS. Because
a previous study reported that RFS could be a surrogatediovascular Surgery c Volume 147, Number 6 1825
TABLE 4. Clinicopathologic findings in patients with clinical stage IA
but pathologic lymph node positive lung adenocarcinoma, according to
lymphatic invasion status
Finding
Lymph node metastasis positive
P
value
Lymphatic
invasion
negative
(n ¼ 13)
Lymphatic
invasion
positive
(n ¼ 28)
Age
Median 64 66 .96
Interquartile range 56-72 55.25-73.25
Sex
Female 4 15 .20
Male 9 13
CEA
Median 3.7 3.4 .81
Interquartile range 2.5-4.075 2.65-4.25
Size*
Median 2 2.2 .62
Interquartile range 1.6-2.6 1.775-2.5
GGOy ratio
Median 0 0 .75
Interquartile range 0-10 0-2.5
SUV max
Median 3.4 3.7 .87
Interquartile range 2.7-4.0 2.175-4.925
LC ratio
Median 10 10 .16
Interquartile range 10-20 0-12.5
Blood vessel invasion
Negative 7 10 .32
Positive 6 18
Pleural invasion
Negative 11 18 .28
Positive 2 10
Lymph node metastasis
N1 9 11 .18
Single station N2 or single
station N2 þ N1
2 11
Multistation N2 2 6
CEA, Carcinoembryonic antigen; GGO, ground-glass opacity; SUV, standardized
uptake value; LC, lepidic component. *Tumor size on the high-resolution computed
tomography scan. yGGO ratio on the high-resolution computed tomography scan.
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assessing OS in identifying prognostic factors.
CONCLUSIONS
LI was not always present in pNþ adenocarcinoma pa-
tients. In addition, pN(þ)LI(–) patients had a better prog-
nosis than pN(þ)LI(þ) patients, whereas there was no
significant difference in RFS between pN(þ)LI(–) and
pN(–)LI(þ) patients with clinical stage IA lung adenocarci-
noma. LI status was indicated to classify clinical T1 N0 M0
lung adenocarcinoma patients with and without lymph node
involvement into good and poor prognosis groups, the pre-
operative staging of which conducted using high-resolution1826 The Journal of Thoracic and Cardiovascular SurCT and FDG-PET/CT. LI status may affect the selection of
patients who have to receive adjuvant therapy.References
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